Eli Lilly Retatrutide Phase 3 Trial Delivers Major Weight Loss
INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...
GLP-1
Advertisement
MetaVia Highlights Vanoglipel’s MASH Fibrosis Potential
CAMBRIDGE, Mass., May 20, 2026 MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic...
Innovent Highlights Obesity Pipeline at ADA 2026
SAN FRANCISCO and SUZHOU, China, May 12, 2026 Innovent Biologics announced that it will present multiple clinical and preclinical...
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Novo Nordisk Expands Wegovy Leadership at ECO 2026
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
Advertisements
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Apotex Gains Canada Approval for Generic Ozempic
Toronto, Canada | May 1, 2026 Apotex has received Health Canada approval for Apo-Semaglutide Injection™, a generic equivalent of...
Lilly Foundayo Shows Strong Phase 3 Diabetes Results
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
Ambrosia Biosciences Raises $100M for GLP-1 Pipeline
BOULDER, Colo., USA — March 31, 2026 Ambrosia Biosciences Inc. has announced the successful completion of a $100 million...
Advertisement
